Video

Dr. Taylor on the Current Treatment Landscape for Endometrial Cancer

Alexandra Taylor, MD, consultant, clinical oncology, The Royal Marsden Hospital, discusses the current treatment landscape of advanced endometrial cancer.

Alexandra Taylor, MD, consultant, clinical oncology, The Royal Marsden Hospital, discusses the current treatment landscape of advanced endometrial cancer.

According to Taylor, the mainstay of treatment is chemotherapy. It is important to give systemic treatment, but if a patient presents with disease that can be surgically removed, there is a debate about whether they should have surgery first.

Ideally, a patient can have complete cytoreduction, meaning they undergo surgery and then receive chemotherapy, explains Taylor. The results with surgery when the patient undergoes cytoreduction can be associated with a high risk of complications.

Related Videos
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD
Jonathan Wesley Riess, MD, MS, an associate professor at the University of California (UC) Davis
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System